Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
The anti-inversion commotion in Washington, D.C., is “more bark than bite” and unlikely to turn into reform in time to damage Medtronic’s $43 billion deal with Covidien, according to analysts with Morgan Stanley.
Democrats have won support from the White House for efforts to penalize companies that relocate their corporate headquarters outside of the U.S. in order to benefit from lower tax rates, but Republicans won’t be so eager to play along, the analysts wrote. Read more
Diabetes devices makers Insulet and DexCom Inc. agreed this week to deepen their partnership, sharing data between in order to support a “personal diabetes manager” (PDM) system currently in development by Insulet.
Under the new agreement DexCom agreed to share data from its 5th-generation continuous glucose monitors with Insulet’s pending wireless PDM technology, which would mean that patients can trade their separate CGM receivers for a mobile app that captures, stores and displays data. Read more
Medtech rivals St. Jude Medical and Volcano signed a truce this week to lay down arms in a long-running legal war that involved multiple technologies and subsidiaries on each side.
The companies agreed to settle all existing litigation between them with prejudice and to refrain from filing lawsuits on those technologies for the next 22 years. Neither party paid or received any money or admitted liability as part of the deal. Read more